Loading news...
Smith and Nephew SNATS (NYSE: SNN) executives struck an optimistic tone in the company's fourth-quarter and full-year 2025 results presentation, pointing to a "strong finish" that landed at the high end of management's guidance for revenue growth, margin expansion, and free cash flow. Chief Executive Officer Deepak Nath said underlying revenue rose 5.3% for the full
Smith+Nephew announces it will feature handheld robotics during the American Academy of Orthopedic Surgeons (AAOS) Annual meeting in New Orleans this week.
Uniting the most advanced technologies for biomechanical repair and biological augmentation Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase its unrivalled portfolio for rotator cuff repair (RCR) during the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans this week. RCR is a growing market segment with approximately 500,000 procedures performed annually in the US,1 yet still experiencing 20–40%2 structural failure rates using traditional surgical techniques.
Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript
Smith+Nephew reported a strong finish to 2025, with profits and cash flow rising as it completed its three-year turnaround plan and set out ambitions for faster growth. Fourth quarter revenue rose 8.3% to $1.7 billion, or 6.2% on an underlying basis, meaning full-year revenue increased 6.1% to $6.2 billion, with underlying growth of 5.3%.
British medical products maker Smith & Nephew posted a 15.5% jump in annual profit on Monday, building on the success of its turnaround plans, which delivered cost savings and boosted growth across its divisions.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed an exclusive US distribution agreement with RMR Ortho to add the A'TOMIC™ Nitinol Fixation System to the Smith+Nephew Trauma, Foot & Ankle and Hand & Wrist portfolio. The system is designed to improve implant integrity and patient comfort1-6—key priorities for surgeons and healthcare systems alike.
Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced it has signed a distribution agreement with SI-BONE, focused on their innovative iFuse TORQ portfolio. This collaboration expands the Smith+Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and strengthens our position in high-frequency, high-impact trauma procedures.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ABC Arbitrage SA lowered its position in shares of Smith and Nephew SNATS, Inc. (NYSE: SNN) by 23.9% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 683,452 shares of the medical equipment provider's stock after selling 215,183 shares
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has completed the acquisition of Integrity Orthopaedics, further strengthening its sports medicine shoulder repair business with the most comprehensive suite of technologies available for rotator cuff repair (RCR).
Summary LARGE CAP INTERNATIONAL PORTFOLIO raised its stake in Smith and Nephew PLC (SNN) by 226.13%, purchasing 29,670 shares to own 42,791 shares valued
SNN expands its Sports Medicine portfolio with Integrity Orthopaedics, adding next-gen Tendon Seam tech to strengthen leadership in shoulder repair.
British medical products maker Smith & Nephew will buy U.S.-based Integrity Orthopaedics in a deal that could be valued at up to $450 million, the company said on Monday.
Smith & Nephew has outperformed peers, driven by strong sports medicine and wound care, despite ongoing ortho business challenges. SNN's major joints segment remains a sore spot, with ongoing underperformance in knees and threats from Stryker's increased focus on ASCs. Management's 6–7% annualized growth guidance through 2028 is ambitious; I expect 5%+ growth with 2-3 points of adjusted EBITDA margin improvement.
Deprince Race and Zollo Inc. lowered its holdings in Smith and Nephew SNATS, Inc. (NYSE: SNN) by 37.3% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 339,883 shares of the medical equipment provider's stock after selling 201,839 shares during the
Smith & Nephew plc (SNN) Analyst/Investor Day Transcript
Smith & Nephew plc (SNN) Analyst/Investor Day Transcript
Smith & Nephew PLC's (LSE:SN) new strategic plan and 2028 outlook look ambitious, City analysts said, but have been received with some heavy dashes of scepticism. UBS, which kept its rating on the shares at 'neutral' and set a 1,290p price target versus a last close at 1,265p, said treating the targets with caution is warranted as the company has achieved growth of over 6% only six times in the past 20 years, "and only two times in the past 15 years (one of which was 2021 COVID recovery)".
Smith & Nephew PLC (LSE:SN) has launched a new corporate strategy designed to give stronger returns for shareholders, alongside issuing medium-term financial targets through to 2028, alongside updated guidance for 2025 and a provisional outlook for accelerating growth in 2026. The knee and hip replacement company named the strategy RISE, as it will drive improved financial and operational performance by focusing on four pillars: Reaching more patients, Innovation, Scaling through investment, and efficient Execution.